Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

3rd Immunotherapy of Cancer Conference (ITOC3) /
Biomarkers in t-cell therapy trials

21st - 23rd Mar 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.04.16
Views: 1501

Dr Jérôme Galon - Laboratory of Integrative Cancer Immunology, Paris, France

Dr Jérôme Galon speaks with ecancertv about his research into T Cell values as a predictive biomarker.

Using his labs Immunoscore assay, Dr Galon reports on the value of memory T Cells as an indicator of early stage patient potential in recovery, and prognosis of late stage patient survival.

These findings indicate that progression of tumour staging can be measured and modulated by host immune response, opposed to host immunity succumbing to disease.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation